Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Cancer Immunology, Immunotherapy : CII
|
June 10, 2008
The E75 HER2/neu peptide vaccine
Elizabeth A Mittendorf, Jarrod P Holmes, Sathibalan Ponniah, et al.
Expert Opinion on Biological Therapy
|
December 10, 2008
CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
Elizabeth A Mittendorf, Jarrod P Holmes, James L Murray, et al.
Military Medicine
|
May 3, 2013
Cancer Vaccine Development Program collaborations
Travis Clifton, Jennifer A Pappas, Maureen Pavlik, et al.
Annals of Surgical Oncology
|
October 2, 2007
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study
Alexander Stojadinovic, Elizabeth A Mittendorf, Jarrod P Holmes, et al.
Journal of the Advanced Practitioner in Oncology
|
August 12, 2024
Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions
Timothy Tyler, Erik Stojanoff, Joan Cannon, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society
|
September 23, 2021
Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
Jarrod P Holmes, Julio A Peguero, R Campbell Garland, et al.
Journal of Surgical Oncology
|
March 24, 2012
The GP2 peptide: a HER2/neu-based breast cancer vaccine
Kevin S Clive, Josh A Tyler, G Travis Clifton, et al.
Cancer
|
November 20, 2009
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, et al.
Expert Review of Vaccines
|
May 11, 2010
Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Kevin S Clive, Josh A Tyler, G Travis Clifton, et al.
Human Vaccines
|
February 16, 2011
Folate receptor α: a storied past and promising future in immunotherapy
Guy T Clifton, Alan K Sears, Kevin S Clive, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Cancer Immunology, Immunotherapy : CII
|
June 10, 2008
The E75 HER2/neu peptide vaccine
Elizabeth A Mittendorf, Jarrod P Holmes, Sathibalan Ponniah, et al.
Expert Opinion on Biological Therapy
|
December 10, 2008
CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
Elizabeth A Mittendorf, Jarrod P Holmes, James L Murray, et al.
Military Medicine
|
May 3, 2013
Cancer Vaccine Development Program collaborations
Travis Clifton, Jennifer A Pappas, Maureen Pavlik, et al.
Annals of Surgical Oncology
|
October 2, 2007
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study
Alexander Stojadinovic, Elizabeth A Mittendorf, Jarrod P Holmes, et al.
Journal of the Advanced Practitioner in Oncology
|
August 12, 2024
Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions
Timothy Tyler, Erik Stojanoff, Joan Cannon, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society
|
September 23, 2021
Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
Jarrod P Holmes, Julio A Peguero, R Campbell Garland, et al.
Journal of Surgical Oncology
|
March 24, 2012
The GP2 peptide: a HER2/neu-based breast cancer vaccine
Kevin S Clive, Josh A Tyler, G Travis Clifton, et al.
Cancer
|
November 20, 2009
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
Mark G Carmichael, Linda C Benavides, Jarrod P Holmes, et al.
Expert Review of Vaccines
|
May 11, 2010
Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Kevin S Clive, Josh A Tyler, G Travis Clifton, et al.
Human Vaccines
|
February 16, 2011
Folate receptor α: a storied past and promising future in immunotherapy
Guy T Clifton, Alan K Sears, Kevin S Clive, et al.
Page
of 3